Pure Global

Ristron - Bright (with lidocaine) - Taiwan Registration 88454298c3459df5984d6b9f9634ef07

Access comprehensive regulatory information for Ristron - Bright (with lidocaine) in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 3 medical device is registered under number 88454298c3459df5984d6b9f9634ef07 and manufactured by Q-MED AB. The authorized representative in Taiwan is GALDERMA HONG KONG LIMITED, TAIWAN BRANCH.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
89,000+ Devices
88454298c3459df5984d6b9f9634ef07
Registration Details
Taiwan FDA Registration: 88454298c3459df5984d6b9f9634ef07
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Ristron - Bright (with lidocaine)
TW: ็‘ž็ตฒๆœ—-ไบฎ้‡‡(ๅซๅˆฉๅคšๅกๅ› )
Risk Class 3

Registration Details

88454298c3459df5984d6b9f9634ef07

DHA05602974801

Company Information

Sweden

Product Details

EMERVEL Deep Lidocaine is available to enhance the fullness of facial tissues. EMERVEL Deep Lidocaine is recommended for correcting severe wrinkles, or beautifying lip shape and cheekbones, depending on the area and tissue support to be treated, this product should be injected into the middle to deep dermis layer, the submucosal layer of the lips, or the subcutaneous tissue. Lidocaine is added to the product to reduce pain during therapeutic injections.

I General, Plastic Surgery and Dermatology

I.0007 Hyaluronic acid implants

Input;; The use of this device shall comply with the provisions of the Administrative Measures for the Implementation or Use of Medical Devices for Specific Medical Technology Inspection and Testing.

Dates and Status

Aug 28, 2017

Aug 28, 2027